{"nctId":"NCT00461591","briefTitle":"Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)","startDateStruct":{"date":"2007-04","type":"ACTUAL"},"conditions":["Bladder Cancer"],"count":802,"armGroups":[{"label":"Apaziquone","type":"EXPERIMENTAL","interventionNames":["Drug: Apaziquone","Procedure: TURBT"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Procedure: TURBT"]}],"interventions":[{"name":"Apaziquone","otherNames":["EOquinÂ®, Qapzola"]},{"name":"Placebo","otherNames":[]},{"name":"TURBT","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: (All questions must be answered YES)\n\n* Has the patient given written informed consent?\n* Is the patient at least 18 years old?\n* Does the patient have transitional cell carcinoma of the bladder with clinically apparent stage Ta, grade G1-G2?\n* If the patient is a female of childbearing potential, is she using an acceptable/effective method of contraception?\n* If the patient is a female of childbearing potential, has she had a negative serum pregnancy test within the past 14 days?\n* Is the patient willing and able to abide by the protocol?\n\nExclusion Criteria: (All questions must be answered NO)\n\n* Does the patient have more than 4 bladder tumors?\n* Does any single bladder tumor exceed 3.5 cm in diameter?\n* Does the patient have a single, primary (no previous diagnosis of TCC) bladder tumor \\<0.5 cm?\n* Has the patient ever received Apaziquone?\n* Does the patient have, or has the patient ever had, any bladder tumor known to be other than stage Ta or grade G1 or G2 (low grade \\[WHO/ISUP classification\\])?\n* Does the patient have, or has the patient ever had any bladder tumor with histology other than transitional cell carcinoma?\n* Does the patient have, or has the patient ever had, carcinoma in situ (CIS)?\n* Does the patient have an active urinary tract infection?\n* Does the patient have a bleeding disorder or a screening platelet count \\< 100 x 10\\^9/L?\n* Does the patient have any unstable medical condition that would make it unsafe for him/her to undergo TURBT under general or spinal anesthesia?\n* Does the patient have a screening hemoglobin \\< 10 mg/dL, a screening absolute neutrophil count \\< 1.5 x 10\\^9/L or a screening creatinine \\> 2 mg/dL?\n* Does the patient have a known immunodeficiency disorder?\n* Has the patient received any investigational treatment within the past 30 days?\n* Is the patient breast feeding?\n* Does the patient have a history of interstitial cystitis?\n* Does the patient have a history of allergy to red color food dye?\n* Has the patient had transitional cell carcinoma of the bladder within the past 4 months?","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recurrence Rate at 2 Years","description":"The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before year 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"121","spread":null}]},{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recurrence","description":"The number of months from randomization to histologically confirmed recurrence of the patient's bladder tumor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"0.47"},{"groupId":"OG001","value":"16.7","spread":"0.55"}]}]}]},{"type":"SECONDARY","title":"Progression Rate at 2 Years","description":"The percentage of participants that progress to either a higher stage or grade from the histologically confirmed stage and grade at time of randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"39","spread":null}]},{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"232","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression","description":"The number of months from randomization to progression to either a higher stage or grade of the patient's bladder tumor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":"0.26"},{"groupId":"OG001","value":"22.0","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Number of Recurrences Per Patient","description":"The number of histologically confirmed recurrences during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.03"},{"groupId":"OG001","value":"0.9","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Disease Free Interval","description":"The number of months from randomization to histologically confirmed progression of the patient's bladder tumor or death from any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":"0.26"},{"groupId":"OG001","value":"22.0","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Disease Free Survival","description":"The number of months from randomization to histologically confirmed recurrence of the patient's bladder tumor or death from any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"0.48"},{"groupId":"OG001","value":"16.4","spread":"0.55"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The number of months from randomization to death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":"0.13"},{"groupId":"OG001","value":"23.7","spread":"0.14"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":93,"n":406},"commonTop":["Dysuria","Urinary tract infection","Haematuria","Pollakiuria","Micturition urgency"]}}}